Stock Analysis
Trevi Therapeutics, Inc. (TRVI) Stock Analysis
Trevi Therapeutics, Inc. (TRVI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Trevi Therapeutics, Inc. (TRVI) currently has an AIQ Score of 63/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Risk is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TRVI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $13.65 |
| AIQ Score | 63/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Neutral |
| Market Cap | $2.18B |
| P/E Ratio (TTM) | -35.2 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.13 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.38 |
| Volume | 1.1M |
| 52-week range | $9.82-$20.22 |
| RSI 14 | 48.45 |
| 50-Day SMA | $14.03 |
| 200-Day SMA | $14.52 |
| Analyst Price Target | — |
| Next Earnings | — |
TRVITrevi Therapeutics, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Sector Leader
Latest quote
- Momentum52
- Value—
- Quality82
- Risk resilience51
- Sentiment—
TRVI Stock Analysis Summary
Trevi Therapeutics, Inc. (TRVI) currently has an AIQ Score of 63/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Risk resilience is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, TRVI has AIQ Score of 63/100 with Quality base of 82/100 and fading Risk resilience at 51/100. Wait for component alignment before adding exposure.
Quality (82/100) leads while Risk resilience (51/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.22% stock move · TRVI classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TRVI Bullish or Bearish Right Now?
TRVI currently has a neutral overall setup. Quality is the strongest factor at 82/100, while Risk Resilience is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 82/100.
- - Price is -6.00% below its 200-day SMA.
Current Consensus
TRVI's Technical Analysis Consensus is currently Neutral, with 19 buy, 8 neutral, and 19 sell votes. TRVI's 14-day RSI is 48.45, which places the stock in a neutral momentum range. TRVI's beta is 1.38, indicating greater market sensitivity than the broad market.
What Changed in TRVI?
The largest recent change in TRVI is Momentum moving up by 2.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the TRVI Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TRVI Decision Framework
Public evidence layers, setup checks, and risk context for Trevi Therapeutics, Inc..
Trevi Therapeutics, Inc. (TRVI) Stock Analysis
Trevi Therapeutics, Inc. has an AIQ Score of 63/100 in a Neutral regime. Quality is strongest at 82/100. Beta is 1.38, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TRVI is in a Neutral AIQ regime with score 63/100. |
| Signal Conflict | The primary conflict is that quality leads at 82/100 while risk lags at 51/100. |
| Factor Evidence | Momentum 52/100 · Quality 82/100 · Risk 51/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 82/100.
Momentum is 52/100 and RSI (14) is 48.5.
TRVI is in a Neutral regime at 63/100.
Risk factor is 51/100 with beta 1.38 and annual volatility 59.27%.
Current conflict: quality leads at 82/100 while risk lags at 51/100.
TRVI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TRVI Fundamentals
TRVI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TRVI Technical Analysis
TRVI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TRVI Stock Catalysts
Track TRVI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TRVI Dividend Analysis
TRVI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TRVI Financial Data
TRVI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TRVI Risk Analysis
TRVI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TRVI Stock News
TRVI stock news, market tone, recent headlines, and catalyst context.
TRVI vs Biotechnology Peers
Current peer cohort: TRVI · TSHA · TVTX · TWST · TYRA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TRVI Current stock | 63/100 | — | 52/100 | 51/100 | 0.52 | 59.27% | Current |
| TSHA Taysha Gene Therapies, Inc. | 35/100 | — | 32/100 | 37/100 | 0.32 | 70.69% | TRVI vs TSHA |
| TVTX Travere Therapeutics, Inc. | 64/100 | 69/100 | 67/100 | 55/100 | 0.87 | 62.28% | TRVI vs TVTX |
| TWST Twist Bioscience Corporation | 64/100 | 58/100 | 84/100 | 32/100 | 1.94 | 84.18% | TRVI vs TWST |
| TYRA Tyra Biosciences, Inc. | 49/100 | — | 27/100 | 45/100 | 0.65 | 67.91% | TRVI vs TYRA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for TRVI: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TRVI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TRVI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TRVI Stock FAQ
What is TRVI stock price today?
Trevi Therapeutics, Inc.'s current stock price is $13.65. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TRVI bullish or bearish right now?
TRVI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TRVI's market cap?
TRVI's market cap is $2.18B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TRVI's current P/E ratio?
TRVI's current P/E ratio is -35.2 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TRVI's RSI?
TRVI's 14-day RSI is 48.45 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TRVI above its 50-day and 200-day moving averages?
TRVI is -2.72% from its 50-day SMA and -6.00% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TRVI's next earnings date?
TRVI's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TRVI pay a dividend?
TRVI's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.